ClinicalTrials.gg
RecruitingNCT07156851BELIEVEUpdated Sep 15, 2026

Observational BELgian Registry of Implanted EV-ICD to Evaluate Parameters and Complications of the New Device in Real World Settings

An observational study in Implantable Cardioverter Defibrillator (ICD), sponsored by AZ Sint-Jan AV. Recruiting at 7 sites in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by AZ Sint-Jan AV · Observational

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this observational study is to follow all patients implanted with extravascular implantable cardioverter-defibrillators (EV-ICDs) in Belgium throughout the lifetime of the devices. The main goal of the study is to keep track of:

  • all parameters of the device
  • complications
  • arrhythmia detection and therapy delivery
  • clinical endpoints (quality of life, cardiac and infectious events) Participants who underwent or will undergo an EV-ICD implantation as part of their regular medical care will be asked if data can be collected from their medical record. No additional tasks are required for the study.
Read the detailed description

The BELIEVE registry (BELgian registry of Implanted EV-ICDs to Evaluate parameters and complications) is a multicenter, observational registry designed to gather real-world data on the use of extravascular implantable cardioverter-defibrillators (EV-ICDs) in Belgium. This new generation of ICD technology offers the potential advantages of both subcutaneous (S-ICD) and transvenous (TV-ICD) devices, with the lead placed under the sternum. This position enables pacing capabilities and more accurate arrhythmia detection while aiming to minimize lead-related complications seen in previous ICD systems.

Given the relatively recent introduction of EV-ICDs, it is essential to monitor their performance and clinical outcomes in routine clinical settings. While initial trials have demonstrated feasibility and safety, real-world data are crucial for understanding long-term efficacy, complication rates, therapy effectiveness, device longevity, and overall patient outcomes. The BELIEVE registry was therefore established to support this need, offering a structured framework to follow patients over time and improve clinical practice related to EV-ICDs.

The registry is both retrospective and prospective, non-randomized, and will include all patients in Belgium who undergo (or have undergone) an EV-ICD implantation-regardless of whether the procedure was successful. Participating centers will aim to enroll an initial cohort of 100 patients over a 4-year period, although the number of patients and study duration may be extended. The total planned study period is 15 years, with patients followed throughout the life of their device.

Inclusion criteria are broad: participants must be at least 18 years old, have had or be scheduled for an EV-ICD implantation (even if unsuccessful), and must provide informed consent. Patients who did not undergo any part of the implantation procedure are excluded.

Data will be collected at baseline, during the procedure, and during scheduled follow-up visits (at 1-3 months, 6 months, and then at least annually). Information will include demographic and clinical characteristics, medical history, device data, arrhythmia detection, therapy delivery, programming changes, complications, and patient-reported outcomes.

02

Conditions studied

  • Implantable Cardioverter Defibrillator (ICD)

Keywords

  • Extravascular implantable cardioverter-defibrillator
  • EV-ICD
03

In context

Lead sponsor

AZ Sint-Jan AV is the lead sponsor of 60 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All patients who underwent or will undergo an EV-ICD implantation in Belgium, whether successful or not, can be included in this registry.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years old
  • Previous or planned EV-ICD implantation (successful or not)
  • signed

Exclusion criteria

Exclusion Criteria:

  • Patients who did not undergo any step of the implantation procedure
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Target follow-up
15 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Number of delivered therapies (ATP and shocks)

    Total number of therapies delivered by the device, including antitachycardia pacing and shocks (Unit: count)

    Time frame: Lifetime of the device (up to 15 years)

  2. Proportion of delivered therapies that were appropriate

    Percentage of therapies delivered by the device that were adjudicated as appropriate (i.e., delivered for true ventricular arrhythmia).

    Time frame: Lifetime of the device (up to 15 years)

  3. Proportion of delivered therapies that were successful

    Percentage of therapies delivered by the device that successfully terminated the targeted ventricular arrhythmia.

    Time frame: Lifetime of the device (up to 15 years)

  4. Tracking procedural and device-related complications

    Tracking procedural and device-related complications during the lifetime of the device

    Time frame: Lifetime of the device (up to 15 years)

Secondary outcomes

  1. Change in sensing amplitude over time

    Change in device-recorded sensing amplitude (in mV) from implantation to follow-up visits.

    Time frame: Lifetime of the device (up to 15 years)

  2. Change in pacing threshold over time

    Change in pacing threshold (in Volt) measured during device follow-up from implantation to 15 years.

    Time frame: Lifetime of the device (up to 15 years)

  3. Change in lead impedance over time

    Change in lead impedance (in Ohm) from implantation to 15 years of follow-up.

    Time frame: Lifetime of the device (up to 15 years)

  4. Change in battery longevity estimates over time

    Change in estimated battery longevity (in years) as reported by the device at each follow-up visit.

    Time frame: Lifetime of the device (up to 15 years)

  5. Accuracy of arrhythmia detection by the device

    Proportion of arrhythmia episodes correctly classified by the device (%)

    Time frame: Lifetime of the device (up to 15 years)

  6. Summary of device reprogramming

    Summary of every device reprogramming including reason for changes

    Time frame: Lifetime of the device (up to 15 years)

  7. Number of participants with major adverse cardiac events (MACE)

    Number of participants experiencing major adverse cardiac events, including cardiovascular death, hospitalization for heart failure, myocardial infarction, or stroke.

    Time frame: Lifetime of the device (up to 15 years)

  8. Number of participants with device-related infections

    Number of participants with infections requiring antibiotic treatment or device/system extraction.

    Time frame: Lifetime of the device (up to 15 years)

  9. Number of participants reporting device-related complaints

    Number of participants reporting device-related symptoms or complaints (e.g., inappropriate shocks, pain at device site).

    Time frame: Lifetime of the device (up to 15 years)

07

Study locations

6 of 7 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Jul 2040, 177 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2025
First posted
Sep 5, 2025
StartActual
Sep 25, 2025
Primary completionEst.
Jul 1, 2040
CompletionEst.
Jul 1, 2040
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07156851
Lead sponsor
AZ Sint-Jan AV
Responsible party
Jean-Benoît Le Polain de Waroux (Coordinating Principal Investigator, AZ Sint-Jan AV) — Principal investigator
First posted
Sep 5, 2025
Start date
Sep 25, 2025
Primary completion
Jul 1, 2040 (estimated)
Completion
Jul 1, 2040 (estimated)
Last update
Sep 15, 2026

Study contacts

Emma Christiaen
Contact
SM-SJ-Cardiologie-Studies@azsintjan.be
+32 50 45 32 93

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion